Retrospective survey-based analysis of 349 COVID-19 patients, showing no significant difference with nigella sativa prophylaxis in unadjusted analysis. REC/UG/2020/03.
risk of severe case, 0.2% lower, RR 1.00, p = 1.00, treatment 4 of 39 (10.3%), control 22 of 214 (10.3%), NNT 4173, unadjusted, severe vs. mild cases.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
This study is excluded in the after exclusion results of meta
analysis:
unadjusted results with no group details.
Shehab et al., 2/28/2022, retrospective, multiple countries, multiple regions, peer-reviewed, survey, 7 authors, study period September 2020 - March 2021.